ADARx Pharmaceuticals, Inc. Common Stock (NASDAQ:ADRX) — Market Cap & Net Worth
Market Cap & Net Worth: ADARx Pharmaceuticals, Inc. Common Stock (ADRX)
ADARx Pharmaceuticals, Inc. Common Stock (NASDAQ:ADRX) has a market capitalization of $1.89 Billion ($1.89 Billion) as of October 12, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6305 globally and #1992 in its home market, demonstrating a -9.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ADARx Pharmaceuticals, Inc. Common Stock's stock price $17.78 by its total outstanding shares 106801325 (106.80 Million).
ADARx Pharmaceuticals, Inc. Common Stock Market Cap History: 2026 to 2026
ADARx Pharmaceuticals, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.90 Billion to $1.90 Billion (0.00% CAGR). Check ADARx Pharmaceuticals, Inc. Common Stock stock price for real-time trading data and today's change.
ADARx Pharmaceuticals, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ADARx Pharmaceuticals, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see ADARx Pharmaceuticals, Inc. Common Stock cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ADRX by Market Capitalization
Companies near ADARx Pharmaceuticals, Inc. Common Stock in the global market cap rankings as of October 12, 2026. See how leveraged is ADARx Pharmaceuticals, Inc. Common Stock's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to ADARx Pharmaceuticals, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
ADARx Pharmaceuticals, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, ADARx Pharmaceuticals, Inc. Common Stock's market cap moved from $1.90 Billion to $ 1.90 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 12th, 2026 the market cap of ADARx Pharmaceuticals, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.89 Billion USD |
| MoneyControl | $1.89 Billion USD |
| MarketWatch | $1.89 Billion USD |
| marketcap.company | $1.89 Billion USD |
| Reuters | $1.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ADARx Pharmaceuticals, Inc. Common Stock
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple ind… Read more